The main objective of the PREVENT study was to assess whether preventive percutaneous coronary intervention (PCI) of non-flow limiting vulnerable plaques improves clinical outcomes compared with optimal medical therapy (OMT) alone.
) PCI BIOTECH HOLDING ASA... As part of this process, the Company approached a limited and targeted group of parties with potential strategic or technological synergies related to PCI Biotech's technology and activities.
) ...PCI Biotech HoldingASA ... PCI Biotech Holding ASA (since 30.01.2026) ... PCI Biotech Holding ASA ... PCI BIOTECH HOLDING. ISIN ... PCI Biotech Holding ASA published this content on February 23, 2026, and is solely responsible for the information contained herein.
To the shareholders of PCI Biotech HoldingASA NOTICE OF EXTRAORDINARY GENERAL MEETING OF PCI BIOTECH HOLDING ASA 16 MARCH 2026. Notice is hereby served that the extraordinary general meeting of PCI Biotech Holding ASA, reg.no..
PCI Biotech HoldingASA. Oslo (Norway), 29 January 2026 - PCI Biotech (OSE... PCI Biotech group's circumstances, the Board has resolved to initiate a process ... The liquidity position of the PCI Biotech group remains critical, casting ... PCI BIOTECH HOLDING.
Oslo (Norway), 29 January 2026 – PCI Biotech (OSE. PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic alternatives ... .